AmoyDx® Essential NGS panel got approval from Chinese authority

AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell

Noticias & eventos



Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit

Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA（National Medical Products Administration）approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.

Noticias & eventos



Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China

· Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017 · Merck is the first pharmaceutical company to collaborate with multiple

Noticias & eventos



AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer

June 14, 2016, Xiamen, China -- Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported

Noticias & eventos



Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China

XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine

Noticias & eventos



KRAS Mutation Detection Kit

PRODUCTOS



KRAS/NRAS Mutations Detection Kit

PRODUCTOS



KRAS/NRAS/BRAF Mutations Detection Kit

PRODUCTOS



Essential NGS Panel

A precise NGS panel, focusing on 10 genes which have clear evidence to the targeted therapy.

PRODUCTOS



KRAS-L2-02 Targeted therapies in colorectal cancer—an integrative view by PPPM

Descargar



KRAS-L2-01 Role of the pretreatment 18F-fluorodeoxyglucose positron emission tomography maximal standardized uptake value

Descargar



EGFR-L2-07 KRAS-L2-03 BRAF-L2-03 PIK3CA-L2-01 ROS1-L2-02 Molecular alterations and clinical prognostic factors for

Descargar



BRAF-L2-01 Comparison of Targeted Next-Generation Sequencing (NGS) and Real-Time PCR in the Detection of EGFR, KRAS, and BRAF

Descargar



KRAS-L1-01 BRAF-L1-02 KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients

Descargar



KNBP-L1-01 Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients_ analysis of 1,110

Descargar



Relationship between KRAS and EGFR gene mutations and clinicopathological features in patients with non-small cell lung cancer in China

Zhang Jiexia, Li Shiyue, Zhan Yangqing, Ouyang Ming

Descargar



AmoyDx® Essential NGS panel got approval from Chinese authority

AmoyDx® Essential NGS panel was approved by Chinese National Medical Products Administration (NMPA) on November 20, 2018, for qualitative detection of gene mutations in patients with Non-Small Cell

Noticias & eventos



Amoy Diagnostics achieved China NMPA Approval of Multi-Genes Mutations Detection Kit

Amoy Diagnostics Co., Ltd. (AmoyDx, SHE:300685) announced that NMPA（National Medical Products Administration）approved its Multi-Genes Mutations Detection Kit on Aug 24, 2018.

Noticias & eventos



Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China

· Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017 · Merck is the first pharmaceutical company to collaborate with multiple

Noticias & eventos



AmoyDx ROS1 Diagnostics Test Contributed to a Phase 2 Clinical Study of Crizotinib in Lung Cancer

June 14, 2016, Xiamen, China -- Amoy Diagnostics Co, Ltd. (AmoyDx), a leading provider of cancer molecular diagnostic products and services, announced today that its AmoyDx®ROS1 test successfully supported

Noticias & eventos



Amoy Diagnostics and Illumina Enter Strategic Collaboration for Next-Generation Sequencing Cancer Diagnostics in China

XIAMEN, China & SAN DIEGO--(BUSINESS WIRE)--Amoy Diagnostics Co. Ltd. (ADx) and Illumina, Inc. (NASDAQ: ILMN) today announced a strategic collaboration to accelerate the adoption of precision medicine

Noticias & eventos



KRAS Mutation Detection Kit

PRODUCTOS



KRAS/NRAS Mutations Detection Kit

PRODUCTOS



KRAS/NRAS/BRAF Mutations Detection Kit

PRODUCTOS



Essential NGS Panel

A precise NGS panel, focusing on 10 genes which have clear evidence to the targeted therapy.

PRODUCTOS



KRAS-L2-02 Targeted therapies in colorectal cancer—an integrative view by PPPM

Descargar



KRAS-L2-01 Role of the pretreatment 18F-fluorodeoxyglucose positron emission tomography maximal standardized uptake value

Descargar



EGFR-L2-07 KRAS-L2-03 BRAF-L2-03 PIK3CA-L2-01 ROS1-L2-02 Molecular alterations and clinical prognostic factors for

Descargar



BRAF-L2-01 Comparison of Targeted Next-Generation Sequencing (NGS) and Real-Time PCR in the Detection of EGFR, KRAS, and BRAF

Descargar



KRAS-L1-01 BRAF-L1-02 KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients

Descargar



KNBP-L1-01 Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients_ analysis of 1,110

Descargar



Relationship between KRAS and EGFR gene mutations and clinicopathological features in patients with non-small cell lung cancer in China

Descargar

